statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acquisition of Fusion Pharmaceuticals Completed

Acquisition of Fusion Pharmaceuticals Completed Acquisition of Fusion Pharmaceuticals Completed PR Newswire HAMILTON, ON and BOSTON, June 4, 2024 HAMILTON, ONandBOSTON, June 4, 2024 /PRNewswire...

Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement

Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement PR Newswire HAMILTON, ON and BOSTON, May 31, 2024...

Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca

Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca PR Newswire HAMILTON, ON and BOSTON, May 29, 2024...

Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake

Bloomberg / Contributor / Getty Images

 Key TakeawaysBillionaire Stanley Druckenmiller added more than three dozen new positions to his portfolio in the first quarter, including Apple, Reddit...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGS, DRQ, CVLY, FUSN

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGS, DRQ, CVLY, FUSN SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGS, DRQ, CVLY, FUSN PR Newswire NEW YORK, May 13, 2024 NEW...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, DRQ, FUSN

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, DRQ, FUSN SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, DRQ, FUSN PR Newswire NEW YORK, May 10, 2024 NEW YORK, May 10...

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer Fusion Pharmaceuticals...

FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Fusion Pharmaceuticals Inc. (NasdaqGS: FUSN) to...

Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates

Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical...

Kuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law Firm

Kuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law Firm Kuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law Firm PR Newswire NEW YORK, April 26, 2024 NEW YORK...

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company. It is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production center. Fusion’s deep radiochemistry expertise presents a technology platform that can be replicated to turn internalizing antibodies that have previously demonstrated limited clinical efficacy into highly effective cytotoxic drugs. Fusion’s ability to link effective isotopes to the targeting antibody allows for the creation of optimized agents for both diagnostic imaging and radioimmunotherapy (Precision Medicine). Following positive tumor identification with the imaging agent, treatment with the antibody linked to a therapeutic isotope delivers a cytotoxic payload into the cancer cell. Fusion’s lead product candidate, FPX-01, is a precision RIT that is a product of this innovative approach. FPX-01 has been designed to internalize targeted cancer cells and deliver a lethal and highly localized radioactive payload. The precise targeting of this radiolabeled antibody causes selective and extremely effective cytotoxicity of tumor cells at relatively low doses of radioactivity.

52-Wk High	$21.60
52-Wk Low	$2.31

FUSN Fusion Pharmaceuticals Inc

About

Feed

News

Earnings

Fundamentals